Abstract:Gasdermin D (GSDMD)-mediated pyroptosis has a significant pro-inflammation characteristic due to dramatic secretion of pro-inflammatory substances. However, its role remains unclear in psoriasis as one chronic inflammatory skin disorder with high prevalence. We found that N-terminal GSDMD (N-GSDMD) was aberrantly expressed in epidermis of skin lesion in psoriasis patients and imiquimod-induced psoriasis-like dermatitis (IIPLD) mice. In epidermis of IIPLD mice and M5 (simulating psoriatic inflammatory challenge)-treated keratinocytes cultured in vitro, cleavage products of caspase-1, GSDMD and IL-1β were increased. M5-stimulated keratinocyte presented typical pyroptosis morphology accompanied with PI-staining. Gsdmd −/− keratinocytes could not present pyroptosis morphology while stimulated with M5. Electroporation of recombinant N-GSDMD could make the pyroptosis morphology reappear. In Gsdmd −/− mice or keratinocyte-specific Gsdmd conditional knockout mice, we observed the alleviation of psoriatic inflammation and epidermal aberrant expression of Ki-67 and differentiation markers (loricrin and keratin 5) after imiquimod stimulation. Transplanting skin tissue from control mice to Gsdmd −/− mice can evoke the response to imiquimod stimulation in the background of Gsdmd −/− mice (not limited in transplanting area). In M5-stimulated keratinocytes, disulfiram or GSDMD siRNA transfection can inhibit pyroptosis and eliminate disproportionate increases of Ki-67 and PI. We further validated that topically application of disulfiram (pyroptosis inhibitor) also alleviated IIPLD in mice. These findings indicate a novel mechanism that GSDMD-mediated keratinocyte pyroptosis facilitates hyperproliferation and aberrant differentiation induced by immune microenvironment in psoriatic skin inflammation, which contributes to pathogenesis of psoriasis. Our study provides an innovative insight that targeting pyroptosis can be considered as a therapeutic strategy against psoriasis.

Group A Streptococcus induces GSDMA-dependent pyroptosis in keratinocytes

Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis

Gasdermin D in pyroptosis

Gasdermin-mediated Pyroptosis Confers Anticancer Immunity

Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors

The gasdermin family: emerging therapeutic targets in diseases

The activation of AIM2/Caspase-1/GSDMD pathway contributes to pyroptosis of keratinocytes in Stevens-Johnson syndrome/toxic epidermal necrolysis

Pore formation by GSDMD is the effector mechanism of pyroptosis

Gasdermin D-mediated keratinocyte pyroptosis as a key step in psoriasis pathogenesis

Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores

Gasdermin D-Mediated Neutrophil Pyroptosis drives Inflammation in Psoriasis

Gasdermin E promotes translocation of p65 and c-jun into nucleus in keratinocytes for progression of psoriatic skin inflammation

Inverse regulation of GSDMD and GSDME gene expression during LPS-induced pyroptosis in RAW264.7 macrophage cells

Gasdermin D:The killer protein performs cell pyroptosis

Downstream of gasdermin D cleavage, a Ragulator-Rag-mTORC1 pathway promotes pore formation and pyroptosis

Full-length GSDME mediates pyroptosis independent from cleavage

GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity.

GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death

Gasdermin D triggers cardiolipin-driven mitochondrial damage and pyroptosis